Esketamine nasal spray in severe bipolar depression with borderline personality disorder and history of multiple substance abuse: A case report.
Bipolar Disorders August 10, 2023 DOI: 10.1111/bdi.13375 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Topics | Depression Esketamine |
Abstract
Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Citations in the library
Cited by 7
- Is there a risk of esketamine misuse in clinical practice? Therapeutic advances in drug safety 2025
- Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management Frontiers in Psychiatry December 8, 2023
- Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness Australian & New Zealand Journal of Psychiatry September 20, 2025
- Psychedelics as a potential treatment for borderline personality disorder: A narrative review. Psychiatry Research July 1, 2026
- Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS. International Journal of Psychiatry in Clinical Practice March 11, 2026
and 2 more in the library
Cites 4
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study American Journal of Psychiatry May 21, 2019
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression JAMA Psychiatry June 5, 2019
- Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment‐resistant depression Bipolar Disorders January 13, 2023
- Intranasal esketamine use in bipolar disorder: A case report Mental Health Clinician July 1, 2021